The CHRYSALIS study [46] demonstrated clinical benefits of Amivantamab (EGFR‐MET bi‐specific antibody) and Lazertinib (third‐generation EGFR‐TKI) in patients with Osimertinib‐relapsed EGFR‐mutated NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.